Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation

American Journal of Cardiology

Volumn 108, Issue 2, 2011, Pages 214-219

  Kitahara, Hideki ^a   Kobayashi, Yoshio ^a   Iwata, Yo ^a   Fujimoto, Yoshihide ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; RAPAMYCIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; LEG EDEMA; MALE; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ACETYLCHOLINE; AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SIROLIMUS; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 79959735464     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.03.029     Document Type: Article

References (29)

1. M. Togni, S. Windecker, R. Cocchia, P. Wenaweser, S. Cook, M. Billinger, B. Meier, and O.M. Hess Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction J Am Coll Cardiol 46 2005 231 236 (Pubitemid 40966848)
2. S.H. Hofma, W.J. van der Giessen, B.M. van Dalen, P.A. Lemos, E.P. McFadden, G. Sianos, J.M. Ligthart, D. van Essen, P.J. de Feyter, and P.W. Serruys Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation Eur Heart J 27 2006 166 170 (Pubitemid 43069032)
3. S. Fuke, K. Maekawa, K. Kawamoto, H. Saito, T. Sato, T. Hioka, and T. Ohe Impaired endothelial vasomotor function after sirolimus-eluting stent implantation Circ J 71 2007 220 225 (Pubitemid 46182696)
4. M.I. Hamilos, M. Ostojic, B. Beleslin, D. Sagic, L. Mangovski, S. Stojkovic, M. Nedeljkovic, D. Orlic, B. Milosavljevic, D. Topic, N. Karanovic, W. Wijns NOBORI CORE Investigators Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion J Am Coll Cardiol 51 2008 2123 2129 (Pubitemid 351721001)
5. K.P. Lakshmana, Y. Xinhua, L. Jinsheng, P.C. Jack, C. Nicolas, and H. Dongming The first-generation drug-eluting stents and coronary endothelial dysfunction J Am Coll Cardiol Intv 2 2009 1169 1177
6. Y.J. Hannele Drug therapy: thiazolidinediones N Engl J Med 351 2004 1106 1118
7. Q.N. Diep, M. El Mabrouk, J.S. Cohn, D. Endemann, F. Amiri, A. Virdis, M.F. Neves, and E.L. Schiffrin Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma Circulation 105 2002 2296 2302 (Pubitemid 34535341)
8. F. Pistrosch, J. Passauer, S. Fischer, K. Fuecker, M. Hanefeld, P. Gross, F. Pistrosch, J. Passauer, S. Fischer, K. Fuecker, M. Hanefeld, and P. Gross In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control Diabetes Care 27 2004 484 490 (Pubitemid 38174076)
9. J. Whrle, N. Marx, W. Koenig, V. Hombach, H.A. Kestler, M. Hher, and T. Nusser Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease Clin Res Cardiol 97 2008 726 733
10. A. Colombo, D. Orlic, G. Stankovic, N. Corvaja, V. Spanos, M. Montorfano, F. Liistro, M. Carlino, F. Airoldi, A. Chieffo, and C. Di Mario Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation Circulation 107 2003 2178 2180 (Pubitemid 36547208)
11. M. Sanmartin, J. Goicolea, R. Castellanos, M. Bravo, R. Ocaranza, D. Cuevas, R. Mantilla, and R. Ruiz-Salmeron Validation of 4 French catheters for quantitative coronary analysis: in vivo variability assessment using 6 French guiding catheters as reference scaling devices J Invasive Cardiol 16 2004 113 116 (Pubitemid 38326319)
12. G.S. Mintz, S.E. Nissen, W.D. Anderson, S.R. Bailey, R. Erbel, P.J. Fitzgerald, F.J. Pinto, K. Rosenfield, R.J. Siegel, E.M. Tuzcu, and P.G. Yock American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS): a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 37 2001 1478 1492
13. J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, C. Morger, N. Kukreja, P. Jni, G. Sianos, G. Hellige, R.T. van Domburg, O.M. Hess, E. Boersma, B. Meier, S. Windecker, and P.W. Serruys Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
14. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 1988 411 415 (Pubitemid 18090241)
15. R.F. Furchgott, and P.M. Vanhoutte Endothelium-derived relaxing and contracting factors FASEB J 3 1989 2007 2018 (Pubitemid 19187609)
16. P.M. Vanhoutte Endothelial dysfunction: the first step toward coronary arteriosclerosis Circ J 73 2009 595 601
17. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefbvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilhelmsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Korányi, M. Laakso, M. Mokán, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Skrha, U. Smith, J. Taton PROactive Investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (PROspective pioglitazone Clinical Trial In macrovascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
18. S.E. Nissen, S.J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochellire, C.S. Staniloae, K. Mavromatis, J. Saw, B. Hu, A.M. Lincoff, E.M. Tuzcu PERISCOPE Investigators Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573 (Pubitemid 351482795)
19. N. Marx, H. Duez, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells Circ Res 94 2004 1168 1178 (Pubitemid 38656403)
20. A. Pftzner, N. Marx, G. Lbben, M. Langenfeld, D. Walcher, T. Konrad, and T. Forst Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study J Am Coll Cardiol 45 2005 1925 1931 (Pubitemid 40814110)
21. G. Lupattelli, S. Marchesi, R. Lombardini, D. Siepi, F. Bagaglia, M. Pirro, G. Ciuffetti, G. Schillaci, and E. Mannarino Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia Metabolism 52 2003 1191 1195 (Pubitemid 37203494)
22. M. Torigoe, H. Matsui, Y. Ogawa, H. Murakami, R. Murakami, X.W. Cheng, Y. Numaguchi, T. Murohara, and K. Okumura Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men Clin Endocrinol 67 2007 276 281 (Pubitemid 47076306)
23. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells Arterioscler Thromb Vasc Biol 23 2003 52 57 (Pubitemid 36091625)
24. H. Ghanim, R. Garg, A. Aljada, P. Mohanty, Y. Kumbkarni, E. Assian, W. Hamouda, and P. Dandona Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese J Clin Endocrinol Metab 86 2001 1306 1312 (Pubitemid 32323021)
25. P. Mohanty, A. Aljada, H. Ghanim, D. Hofmeyer, D. Tripathy, T. Syed, W. Al-Haddad, S. Dhindsa, and P. Dandona Evidence for a potent antiinflammatory effect of rosiglitazone J Clin Endocrinol Metab 89 2004 2728 2735
26. D. Fukuda, M. Sata, K. Tanaka, and R. Nagai Potent inhibitory effect of sirolimus on circulating vascular progenitor cells Circulation 111 2005 926 931 (Pubitemid 40279896)
27. C.H. Wang, M.K. Ting, S. Verma, L.T. Kuo, N.I. Yang, I.C. Hsieh, S.Y. Wang, A. Hung, and W.J. Cherng Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus Am Heart J 152 2006 e1 e8
28. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
29. A.M. Lincoff, K. Wolski, S.J. Nicholls, and S.E. Nissen Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 2007 1180 1188 (Pubitemid 47403104)